Clinical trial

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

NCT05516498

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part A: zibotentan (dose B) + dapagliflozin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B: placebo (matching zibotentan capsule) + dapagliflozin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B: zibotentan (dose A) + dapagliflozin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B: zibotentan (dose B) + dapagliflozin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Part B: zibotentan (dose C) + dapagliflozin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-10-31

PhasePHASE2

Conditions

Liver Cirrhosisunresolved

Interventions

Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)DRUG

Part A: zibotentan (dose B) + dapagliflozinDRUG

Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)DRUG

Part B: placebo (matching zibotentan capsule) + dapagliflozinDRUG

Part B: zibotentan (dose A) + dapagliflozinDRUG

Part B: zibotentan (dose B) + dapagliflozinDRUG

Part B: zibotentan (dose C) + dapagliflozinDRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

BarcelonaSpain3 MadridSpain2 TaipeiTaiwan2 PragueCzechia2 DallasTexas, United States1 San FranciscoCalifornia, United States1 LondonUnited Kingdom1 ParisFrance1 BirminghamAlabama, United States1 RochesterMinnesota, United States1 CharlestonSouth Carolina, United States1 RichmondVirginia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05516498 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.